All posts by medical

Oral Roflumilast Effective in the Treatment of Plaque Psoriasis – Medpage Today

Oral roflumilast (Daliresp) may be an inexpensive and effective treatment option for patients with psoriasis who are candidates for systemic therapy, according to research presented at the American Academy of Dermatology (AAD) annual meeting.

MedPage Today brought together three expert leaders in the field: moderator Melinda Gooderham, MSc, MD, a dermatologist and clinical researcher from Peterborough, Ontario, is joined by Jennifer Soung, MD, a dermatologist and director of clinical research at Southern California Dermatology in Orange County, and Geeta Yadav, MD, founder of FACET Dermatology in Toronto, for a virtual roundtable discussion. This last of four exclusive episodes focuses on the results of a phase II randomized trial evaluating the efficacy and safety of oral roflumilast in adults with moderate-to-severe plaque psoriasis.

Following is a transcript of their remarks:

Gooderham: Hello, I'm Melinda Gooderham. I'm a dermatologist and clinical researcher from Peterborough, Ontario, at the SKiN Centre for Dermatology and an assistant professor at Queen's University. I wanted to welcome you to this roundtable discussion on top news from AAD 2023, and I'm delighted to have with me today, Dr. Geeta Yadav, who is the founder and medical director at FACET Dermatology in Toronto and a lecturer at the University of Toronto, and Dr. Jennifer Soung, who is the director of clinical research at Southern California Dermatology and is on the clinical faculty at Harbor-UCLA.

All right, so moving on that same theme of PDE4 inhibition, there was another investigator-initiated poster presented at the late-breakers. The efficacy and safety of oral roflumilast in the treatment of moderate-to-severe psoriasis, a randomized, double-blinded, placebo-controlled trial, which they named PSORRO.

This was done in Denmark without any industry funding. So that was an interesting one for the late breakers, it's good for them. So they looked at roflumilast 500 mcg once a day versus placebo for the first 12 weeks. They had 23 patients randomized to each arm. At week 12, the placebo patients rolled over to receive open-label oral roflumilast, the same dose 500 mcg once a day.

So total 24 week study and eligibility criteria were quite similar to any other psoriasis clinical trial with adults. And PASI [Psoriasis Area and Severity Index], BSA [body surface area] similar to the other phase III programs. And they had some baseline characteristics, again that were quite typical -- average age late 30s, two-thirds to three-quarters that were male there in Denmark. So they had 100% Caucasian patients. Their baseline characteristics, the median PASI was about 10, BSA 10 to 14%, sPGA [static Physician's Global Assessment] of 2, with a significant impact on DLQI [Dermatology Life Quality Index] about 9 to 10.

So what they found at the 12-week mark and the primary endpoint being PASI 75 at week 12 was 35% of roflumilast patients achieving the PASI 75 compared to 0%. So there was like no placebo response in that first 12 weeks. Placebo patients then switched over and in 12 weeks they had a 39% PASI 75 rate. So fairly consistent results, and also consistent to what we have seen with other PDE4 inhibitors, such as apremilast [Otezla], in that sort of 30 to 40% range of PASI 75, although it was week 16 with apremilast.

So we saw a nice mean change from baseline and PASI in the drug group. The placebo group had no reduction until they were rolled over onto the drug. And you could see the drug worked well across groups, and even in PASI 90, one-fifth of patients were able to achieve a PASI 90 in this study.

So for tolerability, we know PDE4, as we just discussed, gastrointestinal intolerance seems to be one of the main issues. And here we did see some high rates of diarrhea.

Dr. Yadav, you were mentioning before about the importance of safety and tolerability. What do you think about this AE [adverse event] chart?

Yadav: Yeah, it does make me mindful that it's not just the safety story, it's also the tolerability story. And I think, again, we take some of these things a little bit for granted with the agents that we've had available to our patients in the last decade-plus. And so as we move into adding more therapeutics into our toolbox, I think safety is definitely where the focus is going to be in the next coming years. But also tolerability as we try to kind of broaden the target and find the balance because there's no point in having a drug that's very safe but totally intolerable.

And weirdly when we look at the numbers here, the placebo group had very high rates of diarrhea, like 30%. So it is comparable to the treatment arm. However, it's not sort of, to me, consistent with what I'd expect in like baseline population numbers. And maybe that's just because the number of people in this study was quite small, so maybe it's not reflective.

Gooderham: Yeah, it's interesting because there was 0% efficacy in the placebo, but they had the same AEs. Dr. Soung, what did you think about this poster, or presentation?

Soung: You know, I was really curious because we certainly have many treatments for psoriasis that are highly effective but are expensive. So what makes oral roflumilast here unique is that, one, it's already internationally approved for use in severe COPD [chronic obstructive pulmonary disease]. So we have a history of safety that's established not in our population, but a history of safety. And there are generic versions available in the U.S. So it can be a very inexpensive option, especially for our patients who are non-insured or who are on Medicare and can't afford other treatment options.

So, I'm really curious and happy to see that someone here is exploring oral roflumilast in our psoriasis patients.

Gooderham: Yeah, no, I think that was great. I believe Professor [Alexander] Egeberg said it's cheaper than a Starbucks a day. So I think in Denmark they have the same issues with accessibility and so it is nice to have a medication that can be more affordable for some patients, like, as you say, who are maybe uninsured and don't have access to some other treatment. So that's great.

Tolerability always an issue. We've been dealing with it for years with apremilast. So, many patients take it with no problem, they have no tolerability issues. So I think it's great and hats off to them for going and doing that investigator-initiated study. That's really great.

So I wanted to thank both of you so much again in your crazy busy schedules at the AAD this year to take some time and talk about these late-breaker sessions. I think it's really an exciting time right now, for awhile now in dermatology, with new mechanisms of action, oral therapies, in addition to our biologic therapies. So thanks very much to both of you for taking the time to talk about these today.

Soung: Always a pleasure.

Yadav: Likewise. Thank you.

Watch episode one here: Trial of Novel TYK2 Inhibitor Hits Its Endpoint in Plaque Psoriasis

Watch episode two here: Switch to IL-23 Blocker Yields Deep Responses in Recalcitrant Plaque Psoriasis

Watch episode three here: Orismilast Clears Skin in Moderate-to-Severe Psoriasis

Greg Laub is the Senior Director of Video and currently leads the video and podcast production teams. Follow

See original here:

Oral Roflumilast Effective in the Treatment of Plaque Psoriasis - Medpage Today

Granular Therapeutics to accelerate development of next-generation pipeline for treating mast cell driven diseases – Yahoo Finance

Clinical candidate selection finalised for lead programme targeting mast-cell driven diseases

Dermatology industry veteran Thibaud Portal, PhD appointed as CEO

LONDON, March 30, 2023 /PRNewswire/ --Granular Therapeutics, (Granular) a private biotech company specialising in precision biologic therapies for treating mast cell driven disorders, today announces clinical candidate selection for its lead programme which has demonstrated promising results in initial preclinical studies., Granular has now commenced proof-of-concept (POC) and IND-enabling studies as it prepares for clinical development.

Since starting work on these concepts in 2019 with backing from Medicxi, Granular has gained a deep understanding of the biology of mast cells and their role in chronic inflammatory diseases. It has developed a pipeline of next-generation approaches that selectively target mast cells. This approach can drive direct and specific mast cell inhibition, avoid systemic toxicity and enable safe chronic dosing for mast cell driven diseases such as chronic urticaria or systemic mastocytosis.

Brian Kim, Scientific Advisory Board member of Granular Therapeutics, remarked: "Recent data in the field of mast cell driven diseases like Urticaria have shown that tremendous efficacycan be attained, but safety concerns still remain, especially in chronic disease settings. Granular offers a next generation modalitythat offers the promise of increased selectivity and safety."

As Granular embarks on the development of its mast cell targeting pipeline of therapies towards clinical phases, it has appointed a dermatology expert, Dr Thibaud Portal, as Chief Executive Officer. Thibaud Portal is a dermatology specialist who was previously Head of Prescription Medicines business and strategy at Galderma SA andis also co-founder of multiple dermatology focused start-up companies. Dr Jonny Finlay, who co-founded Granular and oversaw the discovery phases, will continue to advise the company and will serve on its Board of Directors.

Story continues

Thibaud Portal, Chief Executive Officer of Granular Therapeutics, commented: "I am honored and delighted to join the Granularteam. Selective mast cell targeting offers outstanding opportunities to address a range of disease indications with a high unmet medical need. I believe this new approach is a significant advancement in the field of chronic inflammatory diseases and that Granular has most exciting pipeline in the field."

Jonny Finlay, Co-founder and Member of the Board of Directors of Granular Therapeutics said:"Finalising the selection of our first clinical candidate is a critical milestone for our company. It is the ideal time to add new competences to the company in order to optimise the positioning of Granular's innovative portfolio of exciting assets across high priority therapeutic areas in the field of chronic inflammatory diseases."

Francesco De Rubertis, Chairman of Granular Therapeutics, added: "We are pleased to welcome Thibaud to Granular's leadership team at this pivotal time of Company growth. As we approach important inflection points, Thibaud's expertise and knowledge will be invaluable in making defining decisions for the future of our innovative programmes."

About Granular Therapeutics

Granular Therapeutics is a UK-based biotechnology company backed by Medicxi, focusing on treatment of mast cell driven diseases. The company was co-founded by Jonny Finlay and Jamie Coleman. Jonny is an industry veteran withtwo decades of experience in biologics discovery and development in academia, government and pharma whosecareer spanned CBER-FDA, Wyeth and Pfizer before becoming a Biotech entrepreneur and the founder of Biotech UltraHuman which spun out of LockBody Therapeutics (now a Centessa company), and Granular Therapeutics. Jamie has been involved for many years in the interface between software, healthcare and investment and co-founded UK-based tech incubator CodeBase, as well as UltraHuman. Granular's CSO, Orla Cunningham was previously Senior Director of Pfizer's BioMedicine Design Group leading multi-disciplinary teams across diverse research units andsupported discovery programmes from conception through to late-stage development. For further information, please visit http://www.granulartherapeutics.com

About Medicxi

Medicxi is a healthcare-focused investment firm with the mission to create and invest in companies across the full drug development continuum. Leveraging deep expertise in drug development and company creation spanning over two decades, Medicxi invests in early and late-stage therapeutics with a product vision that can fulfill a clear unmet medical need.For more information, please visit: https://www.medicxi.com.

Cision

View original content:https://www.prnewswire.com/news-releases/granular-therapeutics-to-accelerate-development-of-next-generation-pipeline-for-treating-mast-cell-driven-diseases-301785554.html

SOURCE Granula Therapeutics

Read more:

Granular Therapeutics to accelerate development of next-generation pipeline for treating mast cell driven diseases - Yahoo Finance

The Weekly Roundup: March 20-24 – Dermatology Times

Advancements in Understanding the Skin's Microbiomes

Adam Friedman, MD, FAAD, offers highlights from his session at AAD 2023 on how cutaneous dysbiosis plays a role in some common skin conditions.

The impacts of discrimination, harassment, and microaggressions have lasting impact on a clinicians performance, mental health, and career. Heres how to create a respectful culture.

With the recent therapeutic revolution, there has never been a better time to find the right treatment option for your patient suffering from inflammatory diseases.

What can you do when a medication for psoriasis yields a suboptimal response? New data presented at the 2023 AAD Annual Meeting provides valuable insight on next steps for treatment.

Joshua Zeichner, MD, delivered a boot camp on isotretinoin use at AAD 2023, including an overview of newer formulations of the acne drug that could help counter the common absorption challenges.

Patients with common psychocutaneous diseases, including body dysmorphic disorder (BDD), often refuse a psychiatric referral and instead, present to dermatologists and cosmetic surgeons.

A review on breast cancer screenings and procedures on the chest is essential to ensure proper gender-affirming care.

Ronda Farah, MD, FAAD, shares her tips and tricks for treating varying types of alopecia.

The treatment was deemed effective following a phase 3 study.

In a world where she practices dermatology, conducts research, and is a super mom, Alina Bridges, DO has nailed down a strategy to not let emails stress her out.

A key session at the annual meeting will share practical advice and tools to better support you and your patients.

Results from the phase 3 study were presented at an AAD late-breaking research session.

Jack Arbiser, MD, PhD discusses the connection between the skin barrier and anti-aging products.

The use of tanning beds has become a popular practice in society today, however, it remains undisputed that ultraviolet radiation from natural sunlight and indoor tanning machines increases an individuals risk of developing skin cancer.

Sandoz, a Novartis division, expects to launch the new adalimumab biosimilar on July 1, 2023.

By week 24 of the phase 3 study, a quarter of participants felt their vitiligo had improved.

A pair of phase 3 trials met all primary and secondary endpoints after 48 weeks.

A pediatric dermatologist and pediatric allergist translated guidelines into clinical practice at AAD 2023.

Draelos shares her top takeaways from the annual AAD meeting in New Orleans.

Results from the phase 3 DERMIS-1 and DERMIS-2 trials were presented at the 2023 American Academy of Dermatology Annual Meeting.

Timber Pharmaceuticals is on its way to developing the first FDA-approved treatment for congenital ichthyosis subtypes.

Prior use of biologics in patients with plaque psoriasis may not impact the efficacy of risankizumab treatment.

Incytes MCC indication is approved under accelerated approval based on tumor response rate and duration of response.

Phase 3 data of Oleogel-S10 was presented in a late-breaking session at AAD 2023 in New Orleans.

Researchers sought to analyze alopecia areata data in populations historically underrepresented in research.

Researchers were unable to determine a definite correlation.

DermaSensors handheld device is awaiting FDA review.

Miller shares upcoming news from the SDPA and important legislative updates for dermatology physician assistants.

In part 3 of this Frontline Forum series, Joshua Zeichner, MD, FAAD; Hilary Baldwin, MD; Zoe Diana Draelos, MD; Aaron S. Farberg, MD, FAAD; and Leon H. Kircik, MD, discuss the main pillars of acne and topical treatments available for patients with acne.

Pregnant women with atopic dermatitis and psoriasis may require special treatment considerations.

The selective and reversible Janus kinase inhibitor is being studied in several immune-mediated inflammatory diseases.

Study investigators said this system could have significant clinical implications.

The study also found lasting benefits of the supplement for bone density up to age 4.

More than 300 innovative sessions, an engaging exhibit hall, and heartfelt networkingthere was a lot to pack into AAD 2023! Here are the highlights.

Researchers say the impacts may be more harmful than those caused by industrial air pollutants.

Researchers say the treatment is both safe and effective in moderate-to-severe cases.

The UK and Netherlands study assessed tumor response rates among 91 patients.

Originally posted here:

The Weekly Roundup: March 20-24 - Dermatology Times

Experts Weigh In On The Salicylic Acid Body Wash Tweet With Over 15 Million Views – BuzzFeed News

BuzzFeed may collect a share of sales or other compensation from the links on this page if you decide to shop from them. All products were independently selected by our editors, and the prices were accurate and items in stock at the time of publication.

Its rare for a skincare product to go viral on Twitter, so when one does, you pay attention.

This month @kaseyonnuh tweeted a photo of The Perfector Salicylic Acid Body Wash from Naturium with the caption, Everyone should own this body wash youre going to have the prettiest skin. I been using it since October and them childhood scars and stuff gone.

The Tweet has almost 16 million views and over 150,000 bookmarks. I ordered it, of course. But first, I asked dermatologists if it could really have the power to get rid of scars. And if not, what would it be good for?

Salicylic acid has several properties, said Dr. Adeline Kikam, a dermatologist based in South Florida. Its what we call a keratolytic agent, so it breaks down dead skin, and it is comedolytic, meaning its going to unclog your pores.

Advertisement

Dr. Julia Tzu, founder and director of Wall Street Dermatology, explained that it targets the sebum or oil in the pores and also breaks down the keratin that can clog them up, which makes it an effective treatment for acne. Since its an acid, it can also exfoliate the skin, and it has anti-inflammatory properties.

Many products aimed at treating psoriasis, dandruff, or seborrheic dermatitis will also include salicylic acid since it can penetrate deep in the pores, but its particularly beneficial for acne.

Though its not generally used as a scar remedy, Kikam said that it can help improve the appearance of post-inflammatory hyperpigmentation or post-acne dark spots, and shes noticed that the internet tends to equate those conditions with true scarring. If youre looking to treat deep scarring, however, she recommends looking for ingredients like topical retinoids that are able to stimulate collagen and elastin.

The fact that Naturium uses encapsulated salicylic acid in this body wash does set it apart from other products, and it has the potential to be more powerful, according to Kikam.

The encapsulated salicylic acid is a bit like an onion, she said, in that layers peel off over time to continuously release the ingredient into the skin. Its known as a controlled release or time release delivery system.

Studies performed with 2% encapsulated salicylic acid actually show that it has deeper penetration into the skin, and two-fold delivery of the salicylic acid compared to non-encapsulated or free form salicylic acid, she said.

Advertisement

Kikam also loves the other ingredients in this body wash, like glycerin and linoleic acid, which can help replenish moisture and boost ceramide levels to promote a healthy skin barrier. Because salicylic acid works to control oil buildup, it can be drying, just like most acne treatments. Naturium aims to balance that out with these linoleic-rich oils and glycerin.

Still, salicylic acid can irritate sensitive skin. Tzu suggests using this body wash once every three days or so to see if your skin can tolerate it before advancing to everyday use. Another way to mitigate irritation and calm the skin is to incorporate a non-comedogenic moisturizer after you wash, like this CeraVe Moisturizing Cream.

Otherwise, products like The Perfector body wash with salicylic acid are generally safe to use topically with minimal risk. Just make sure to moisturize, dont forget sunscreen so that you can avoid additional irritation or burning, and enjoy the potentially skin-beautifying results. Stay tuned for an update on my own personal journey.

You can buy Naturium The Perfector Salicylic Acid Skin Smoothing Body Wash from Target for around $14.

View original post here:

Experts Weigh In On The Salicylic Acid Body Wash Tweet With Over 15 Million Views - BuzzFeed News

Facial Wrinkle Treatment Market Size To Hit US$ 472.2 billion By … – GlobeNewswire

New York, March 30, 2023 (GLOBE NEWSWIRE) -- As per Persistence Market Research, the global facial wrinkle treatment market was valued at US$ 77.2 billion in 2022 and is projected to surge ahead at a CAGR of 17.9% between 2023 and 2033.Facial Wrinkle Treatment Market is expected to reach US$ 472.2 billion by the end of 2033

Demand for minimally invasive cosmetic treatment procedures is increasing significantly. Dermatologists prefer to treat skin diseases with topical applications or less invasive procedures rather than surgical methods. The most frequently used procedure involving the application of botulinum toxin and dermal filler leads to wrinkle reduction with volume restoration. Social media and mainstream media are the main channels used to reach and influence customers, encouraging them to start early in their efforts to delay the onset of aging.

Growing demand for non-invasive facial wrinkle treatments, easier product approvals, and advancements in technology are boosting strategic activities like distribution and collaboration agreements among manufacturers.

The growth of the facial wrinkle treatment market has been driven by the contribution of dermatology laser equipment and advanced skincare technologies, which have led to various applications of cosmetic treatments. Additionally, the growing demand for skin resurfacing and rejuvenation has prompted the development of some highly innovative solutions.

Click Here to Get Free Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/17239

Developments include several product launches every year.

Companies operating in the facial wrinkle treatment market are focusing on adopting effective strategies to develop new products and expand their distribution network. They focus on product distribution and collaboration agreements with other market players to enhance their position in the facial wrinkle treatment market.

For instance:

Key Takeaways from Market Study

Due to the rising number of minimally invasive procedures and skin treatments being performed worldwide, the facial wrinkle treatment market is expected to exhibit significant growth over the coming years, according to a researcher at Persistence Market Research.

Get Full Access of this Report@ https://www.persistencemarketresearch.com/checkout/17239

Market Competition

Key market participants such as Unilever, Givaudan SA, and LOreal who are manufacturing and bringing new products into their portfolios are prioritizing product development technologies, partnerships, collaborations, mergers, and acquisitions.

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights into the facial wrinkle treatment market in its latest study, presenting a historical demand assessment for 2017 to 2022 and projections for 2023 to 2033.

The research study is based on

You Can Customize this Report As per Your Requirement Click Here@ https://www.persistencemarketresearch.com/request-customization/17239

For additional insights on how the growth of the facial wrinkle treatment market will unfold over the decade, write to the analyst atmedia@persistencemarketresearch.com

Persistence Market Researchs Expertise in Life Sciences and Transformational Health

Our expert team of industry analysts comprising management graduates, medical professionals, engineers, and project managers provides insights on emerging therapy areas, diagnostic tools, medical devices and components, reimbursement and market access, biotechnology, and life sciences research products and services to equip decision-makers with sound inputs and strategic recommendations.

Other Trending Reports:

About Persistence Market Research:

Business intelligence is the foundation of every business model employed by Persistence Market Research. Multi-dimensional sources are being put to work, which include big data, customer experience analytics, and real-time data collection. Thus, working on micros by Persistence Market Research helps companies overcome their macro business challenges.Persistence Market Research is always way ahead of its time. In other words, it tables market solutions by stepping into the companies/clients shoes much before they themselves have a sneak pick into the market. The pro-active approach followed by experts at Persistence Market Research helps companies/clients lay their hands on techno-commercial insights beforehand, so that the subsequent course of action could be simplified on their part.

Contact

Rajendra SinghPersistence Market ResearchU.S. Sales Office:305 Broadway, 7th FloorNew York City, NY 10007+1-646-568-7751United StatesUSA - Canada Toll-Free: 800-961-0353Email: sales@persistencemarketresearch.com

Original post:

Facial Wrinkle Treatment Market Size To Hit US$ 472.2 billion By ... - GlobeNewswire

Have AI Chatbots Developed Theory of Mind? What We Do and Do … – The New York Times

Mind reading is common among us humans. Not in the ways that psychics claim to do it, by gaining access to the warm streams of consciousness that fill every individuals experience, or in the ways that mentalists claim to do it, by pulling a thought out of your head at will. Everyday mind reading is more subtle: We take in peoples faces and movements, listen to their words and then decide or intuit what might be going on in their heads.

Among psychologists, such intuitive psychology the ability to attribute to other people mental states different from our own is called theory of mind, and its absence or impairment has been linked to autism, schizophrenia and other developmental disorders. Theory of mind helps us communicate with and understand one another; it allows us to enjoy literature and movies, play games and make sense of our social surroundings. In many ways, the capacity is an essential part of being human.

What if a machine could read minds, too?

Recently, Michal Kosinski, a psychologist at the Stanford Graduate School of Business, made just that argument: that large language models like OpenAIs ChatGPT and GPT-4 next-word prediction machines trained on vast amounts of text from the internet have developed theory of mind. His studies have not been peer reviewed, but they prompted scrutiny and conversation among cognitive scientists, who have been trying to take the often asked question these days Can ChatGPT do this? and move it into the realm of more robust scientific inquiry. What capacities do these models have, and how might they change our understanding of our own minds?

Psychologists wouldnt accept any claim about the capacities of young children just based on anecdotes about your interactions with them, which is what seems to be happening with ChatGPT, said Alison Gopnik, a psychologist at the University of California, Berkeley and one of the first researchers to look into theory of mind in the 1980s. You have to do quite careful and rigorous tests.

Dr. Kosinskis previous research showed that neural networks trained to analyze facial features like nose shape, head angle and emotional expression could predict peoples political views and sexual orientation with a startling degree of accuracy (about 72 percent in the first case and about 80 percent in the second case). His recent work on large language models uses classic theory of mind tests that measure the ability of children to attribute false beliefs to other people.

A brave new world. A new crop of chatbotspowered by artificial intelligence has ignited a scramble to determine whether the technology could upend the economics of the internet, turning todays powerhouses into has-beens and creating the industrys next giants. Here are the bots to know:

ChatGPT. ChatGPT, the artificial intelligence language model from a research lab, OpenAI, has been making headlines since November for its ability to respond to complex questions, write poetry, generate code, plan vacationsand translate languages. GPT-4, the latest version introduced in mid-March, can even respond to images(and ace the Uniform Bar Exam).

Bing. Two months after ChatGPTs debut, Microsoft, OpenAIs primary investor and partner, added a similar chatbot, capable of having open-ended text conversations on virtually any topic, to its Bing internet search engine. But it was the bots occasionally inaccurate, misleading and weird responsesthat drew much of the attention after its release.

Ernie. The search giant Baidu unveiled Chinas first major rival to ChatGPT in March. The debut of Ernie, short for Enhanced Representation through Knowledge Integration, turned out to be a flopafter a promised live demonstration of the bot was revealed to have been recorded.

A famous example is the Sally-Anne test, in which a girl, Anne, moves a marble from a basket to a box when another girl, Sally, isnt looking. To know where Sally will look for the marble, researchers claimed, a viewer would have to exercise theory of mind, reasoning about Sallys perceptual evidence and belief formation: Sally didnt see Anne move the marble to the box, so she still believes it is where she last left it, in the basket.

Dr. Kosinski presented 10 large language models with 40 unique variations of these theory of mind tests descriptions of situations like the Sally-Anne test, in which a person (Sally) forms a false belief. Then he asked the models questions about those situations, prodding them to see whether they would attribute false beliefs to the characters involved and accurately predict their behavior. He found that GPT-3.5, released in November 2022, did so 90 percent of the time, and GPT-4, released in March 2023, did so 95 percent of the time.

The conclusion? Machines have theory of mind.

But soon after these results were released, Tomer Ullman, a psychologist at Harvard University, responded with a set of his own experiments, showing that small adjustments in the prompts could completely change the answers generated by even the most sophisticated large language models. If a container was described as transparent, the machines would fail to infer that someone could see into it. The machines had difficulty taking into account the testimony of people in these situations, and sometimes couldnt distinguish between an object being inside a container and being on top of it.

Maarten Sap, a computer scientist at Carnegie Mellon University, fed more than 1,000 theory of mind tests into large language models and found that the most advanced transformers, like ChatGPT and GPT-4, passed only about 70 percent of the time. (In other words, they were 70 percent successful at attributing false beliefs to the people described in the test situations.) The discrepancy between his data and Dr. Kosinskis could come down to differences in the testing, but Dr. Sap said that even passing 95 percent of the time would not be evidence of real theory of mind. Machines usually fail in a patterned way, unable to engage in abstract reasoning and often making spurious correlations, he said.

Dr. Ullman noted that machine learning researchers have struggled over the past couple of decades to capture the flexibility of human knowledge in computer models. This difficulty has been a shadow finding, he said, hanging behind every exciting innovation. Researchers have shown that language models will often give wrong or irrelevant answers when primed with unnecessary information before a question is posed; some chatbots were so thrown off by hypothetical discussions about talking birds that they eventually claimed that birds could speak. Because their reasoning is sensitive to small changes in their inputs, scientists have called the knowledge of these machines brittle.

Dr. Gopnik compared the theory of mind of large language models to her own understanding of general relativity. I have read enough to know what the words are, she said. But if you asked me to make a new prediction or to say what Einsteins theory tells us about a new phenomenon, Id be stumped because I dont really have the theory in my head. By contrast, she said, human theory of mind is linked with other common-sense reasoning mechanisms; it stands strong in the face of scrutiny.

In general, Dr. Kosinskis work and the responses to it fit into the debate about whether the capacities of these machines can be compared to the capacities of humans a debate that divides researchers who work on natural language processing. Are these machines stochastic parrots, or alien intelligences, or fraudulent tricksters? A 2022 survey of the field found that, of the 480 researchers who responded, 51 percent believed that large language models could eventually understand natural language in some nontrivial sense, and 49 percent believed that they could not.

Dr. Ullman doesnt discount the possibility of machine understanding or machine theory of mind, but he is wary of attributing human capacities to nonhuman things. He noted a famous 1944 study by Fritz Heider and Marianne Simmel, in which participants were shown an animated movie of two triangles and a circle interacting. When the subjects were asked to write down what transpired in the movie, nearly all described the shapes as people.

Lovers in the two-dimensional world, no doubt; little triangle number-two and sweet circle, one participant wrote. Triangle-one (hereafter known as the villain) spies the young love. Ah!

Its natural and often socially required to explain human behavior by talking about beliefs, desires, intentions and thoughts. This tendency is central to who we are so central that we sometimes try to read the minds of things that dont have minds, at least not minds like our own.

Follow this link:
Have AI Chatbots Developed Theory of Mind? What We Do and Do ... - The New York Times

Here’s five fall 2023 classes to fire up your bookbag – Duke Chronicle

Feel like experimenting with your classes this fall? As shopping carts for fall 2023 classes opened on Monday, The Chronicle compiled a list of interesting courses across a range of disciplines that you can take in the upcoming semester. Registration begins on April 5 and ends April 13.

Taught by Cole L. Russing

Th 10:05 a.m.-12:35 p.m.

Course Credits: ENGLISH 225S, CINE 306S, VMS 360S (ALP, W)

Are you a lover of Letterboxd? Do you have a script idea you believe belongs on Netflix? This course will teach students how to turn story ideas into a screenplay. Students will have the opportunity to analyze screenplays and movies, develop a deeper understanding of visual storytelling and create their own scenes.

Charmaine D. Royal

MW 11:45 a.m.-1 p.m.

Course Credits: AAS 261D, BIOLOGY 261D, CULANTH 261D, GLHLTH 258D, SCISOC 258D, VMS 274D (EI, STS, NS, SS)

Interested in engaging with challenges related to race and genetics? This course explores human origins, human variation, human identity, and human health to reflect on the concept of race within the field of genetics on a global scale. Scientific, ethical, legal, societal, cultural and psychosocial issues surrounding the concept of race will be discussed. Students from any discipline in the arts, humanities and sciences are welcome.

Taught by Kimberly K. Lamm

MW 10:05-11:20 a.m.

Course Credits: AAAS 355S, ARTSVIS 353S, ENGLISH 353S, GSF 355S, LIT 355S (CCI, W, ALP)

This course focuses on Black feminist perspectives on clothing and fashion, and reveals fashion and clothing as aesthetic practices of everyday life that defy the objectifying effects of racism and sexism.

Students will analyze the photos, paintings and literature of Black artists and writers in which clothing is a primary theme. They will further explore slaverys and colonialisms impact on gender and sexuality.

Taught by Margaret Humphreys

TuTh 8:30-9:45 a.m.

Course Credits: HISTORY 371, SCISOC 371 - 01 (CCI, STS, CZ, SS)

Feeling hungry?

This course takes a dive into the history of food, from the Paleolithic era today. It explores food exchanges across continents and cultures, discovery of vitamins and vitamin deficiencies, growth and impact of food industries, and the rise of diseases. It also considers the intersection of food and health, looking at food insecurity and obesity.

Taught by John Forlines III

Th 1:25-3:55 p.m.

Course Credits: ECON 255S, PUBOL 257S (CCI, SS)

Wondering how you can use Shakespeare to understand human behavior in the modern financial market? This course will analyze plays like Hamlet, Julius Caesar and Twelfth Night and use their themes to better understand current socioeconomic trends. Lessons will look at policy errors, cultural and political dislocation, regime changes [and] demographic conflicts.

CORRECTION: A previous version of the article listed Sexual Pleasure in the Modern World as a class being offered next fall. This class is being taught this spring and is not offered next fall. The class has been replaced with Feast and Famine: Food in Global History in this article. The Chronicle regrets the error.

Signup for our weekly newsletter. Cancel at any time.

Ayra Charania is a Trinity junior and a senior editor of The Chronicle's 118th volume.

Continue reading here:
Here's five fall 2023 classes to fire up your bookbag - Duke Chronicle

Scoop: Coming Up on a New Episode of HOUSEBROKEN on FOX … – Broadway World

Guest-Starring Melanie Lynsky ("Yellowjackets")

When Honey attempts to cure Diablo's irrational fear of basement monsters, she puts the whole group in jeopardy. Chico and The Gray One follow Kevin onto a plane to get to the bottom of why Kevin always abandons Chico. Chief faces off against the loud barking dog in the sky, more commonly known as thunder, in the all-new "Who's A Scaredy Cat?" episode of HOUSEBROKEN airing Sunday, April 2 (9:30-10:00 PM ET/PT) on FOX.

Featuring the voices of Lisa Kudrow, Will Forte, Clea DuVall, Nat Faxon, Sharon Horgan, Tony Hale, Sam Richardson and Jason Mantzoukas, animated comedy HOUSEBROKEN follows a group of neighborhood pets and stray animals as they work through their issues inside and outside their therapy group.

HONEY (Emmy Award winner Lisa Kudrow, "Friends," "The Comeback") opens her living room for the group to come and support each other through the misery, mayhem and majesty that is being a pet. Honey also struggles with her own problems, such as her arranged (by her human) marriage with CHIEF (Academy Award winner Nat Faxon, "The Descendants," "The Way Way Back"), a sloppy St. Bernard who enjoys eating socks and licking himself.

The group includes SHEL (Emmy Award nominee Will Forte, "The Last Man on Earth," "Nebraska"), a sex positive tortoise with intimacy issues and a knack for choosing unconventional partners; TABITHA (Emmy Award nominee Sharon Horgan, "Catastrophe"), an aging Persian cat beauty queen, trying to adjust to life off the cat show circuit; THE GRAY ONE (Jason Mantzoukas, "Brooklyn Nine-Nine," "The Good Place"), a street smart cat who lives with about 30 other cats and has his one eye on Tabitha; CHICO (Screen Actors Guild Award winner Sam Richardson, "Veep"), a chonky, co-dependent and very naive cat; and the group's newest member, DIABLO (Emmy Award winner Tony Hale, "Veep," "Arrested Development"), an anxious, sweater-wearing terrier whose OCD causes him to hump everything twice.

Among the group's other members are ELSA (Screen Actors Guild Award winner Clea DuVall, "The Handmaid's Tale," "Veep"), a power hungry, know-it-all Corgi and fake service dog, who drives Honey crazy; NIBBLES (guest voice Bresha Webb, "The Last O.G."), a psychopathic hamster who is mourning the loss of her mate (whose face she ate...and everyone knows it); MAX (Hale), George Clooney's pig, a former actor and current status-obsessed a-hole; BUBBLES (guest voice Greta Lee, "Russian Doll"), a horny, teenage goldfish who lives with Honey and Chief, and heckles the animals any chance she gets; TCHOTCHKE, a silent, and possibly magical, slow loris with a mysterious past, who uses a tiny cocktail umbrella to express his emotions; and JILL (guest voice Maria Bamford, "Big Mouth," "BoJack Horseman"), Honey and Chief's human owner. But who cares? This is about animals.

HOUSEBROKEN is an irreverent look at human behavior, but told through the filter of a quirky group of neighborhood pets. Throughout the series, the show centers on the pets' dysfunctional relationships and their skewed world view, while exploring relevant societal issues in fun and unique ways.

HOUSEBROKEN is produced by Kapital Entertainment and FOX Entertainment. It is created and executive-produced by Gabrielle Allan, Jennifer Crittenden and Clea DuVall. Sharon Horgan, Clelia Mountford, Aaron Kaplan and Dana Honor also serve as executive producers. The series is animated by Bento Box Entertainment.

Watch a clip here:

More here:
Scoop: Coming Up on a New Episode of HOUSEBROKEN on FOX ... - Broadway World